ADB-5'Br-BUTINACA
Chemical compound
 | |
| Identifiers | |
|---|---|
| |
| PubChem CID |
|
| ChemSpider |
|
| Chemical and physical data | |
| Formula | C18H25BrN4O2 |
| Molar mass | 409.328 g·mol−1 |
| 3D model (JSmol) |
|
| |
InChI
| |
ADB-5'Br-BUTINACA (ADB-B-5Br-INACA) is an indazole-3-carboxamide based synthetic cannabinoid receptor agonist which has been sold as a designer drug,[1] first detected in Philadelphia in the US in May 2022,[2] and subsequently found in South Korea,[3] Portugal and Sweden.[4] It is specifically listed as an illegal drug in Italy,[5] South Korea[6] and several states in the US,[7][8] and controlled under analogue legislation in various other jurisdictions.
See also
- ADB-BUTINACA
- ADB-5'Br-PINACA
- ADB-5'F-BUTINACA
- ADSB-FUB-187
- MDMB-5'Br-BUTINACA
- MDMB-BINACA
References
- ^ Deventer MH, Persson M, Norman C, Liu H, Connolly MJ, Daéid NN, McKenzie C, Gréen H, Stove CP (October 2023). "In vitro cannabinoid activity profiling of generic ban-evading brominated synthetic cannabinoid receptor agonists and their analogs". Drug Testing and Analysis. doi:10.1002/dta.3592. PMID 37903509. S2CID 264671035.
- ^ "ADB-5'Br-BINACA" (PDF). CFSRE Chemistry Report. The Center for Forensic Science Research & Education.
- ^ Kim J, Yum H, Kang S, Lee N, Song J, Park Y, Choe S, Park M (November 2023). "Comprehensive evaluation of drug cases in Seoul and its metropolitan areas - 2022". Forensic Science International. 353: 111877. doi:10.1016/j.forsciint.2023.111877. PMID 37989071. S2CID 265022768.
- ^ "Yttrande enligt 13 § Lag (2011:111) om förstörande av vissa hälsofarliga missbrukssubstanser" [Opinion according to § 13 Act (2011:111) on the destruction of certain substances of abuse dangerous to health] (PDF) (in Swedish). The Public Health Authority.
- ^ "Aggiornamento delle tabelle contenenti l'indicazione delle sostanze stupefacenti e psicotrope, di cui al decreto del Presidente della Repubblica 9 ottobre 1990, n. 309 e successive modificazioni e integrazioni. Inserimento nella Tabella I di nuove sostanze psicoattive. (23A01072)" [Update of the tables containing the indication of the substances narcotic and psychotropic drugs, referred to in the decree of the President of the Republic 9 October 1990, n. 309 and subsequent amendments e integrations. Inclusion of new substances in Table I psychoactive. (23A01072)] (in Italian). Italy: Ministry of Health. 13 February 2023.
- ^ "˝에이디비-5'비알-부티나카˝ 등 3종 임시마약류 지정예고" [Announcement of temporary designation of 3 types of narcotics, including “ADB-5 ‘BR-Butinaka’”]. Korean Food and Drug Daily News (in Korean).
- ^ "18VAC110-20-322. Placement of chemicals in Schedule I." Administrative Code. Commonwealth of Virginia.
- ^ "Section 19-03.1-05 - Schedule I, N.D. Cent. Code § 19-03.1-05". North Dakota Century Code.
- v
- t
- e
Cannabinoids
(comparison)
| Cannabibutols |
|
|---|---|
| Cannabichromenes | |
| Cannabicyclols |
|
| Cannabidiols | |
| Cannabielsoins |
|
| Cannabigerols | |
| Cannabiphorols |
|
| Cannabinols | |
| Cannabitriols |
|
| Cannabivarins |
|
| Delta-8-tetrahydrocannabinols |
|
| Delta-9-tetrahydrocannabinols | |
| Delta-10-Tetrahydrocannabinols | |
| Miscellaneous cannabinoids |
|
| Active metabolites |
- Arachidonoyl ethanolamide (AEA; anandamide)
- 2-Arachidonoylglycerol (2-AG)
- 2-Arachidonyl glyceryl ether (2-AGE; noladin ether)
- 2-Oleoylglycerol (2-OG)
- N-Arachidonoyl dopamine (NADA)
- N-Arachidonylglycine (NAGly)
- 2-Arachidonoyl lysophosphatidylinositol (2-ALPI)
- N-Arachidonoyl serotonin (AA-5-HT)
- Docosatetraenoylethanolamide (DEA)
- Lysophosphatidylinositol (LPI)
- Oleamide
- Oleoylethanolamide (OEA)
- Palmitoylethanolamide (PEA)
- RVD-Hpα
- Stearoylethanolamide (SEA)
- O-Arachidonoyl ethanolamine (O-AEA; virodhamine)
cannabinoid
receptor
agonists /
neocannabinoids
enhancers
(inactivation inhibitors)
- 4-Nonylphenylboronic acid
- AM-404
- Arachidonoyl serotonin
- Arvanil
- BIA 10-2474
- Biochanin A
- CAY-10401
- CAY-10429
- Genistein
- Guineesine
- IDFP
- JNJ 1661010
- JNJ-42165279
- JZL184
- JZL195
- Kaempferol
- LY-2183240
- MK-4409
- O-1624
- O-2093
- Oleoylethanolamide (OEA)
- Olvanil
- Palmitoylethanolamide (PEA)
- PF-04457845
- PF-622
- PF-750
- PF-3845
- PHOP
- URB-447
- URB-597
- URB-602
- URB-754
- VDM-11
(antagonists/inverse
agonists/antibodies)
- AM-251
- AM-281
- AM-630
- AM-1387
- AM-4113
- AM-6527
- AM-6545
- BML-190
- Brizantin (Бризантин)
- CAY-10508
- CB-25
- CB-52
- CB-86
- Dietressa (Диетресса)
- Drinabant (AVE1625)
- Hemopressin
- Ibipinabant (SLV319)
- JTE-907
- LH-21
- LY-320,135
- MDA-77
- MJ-15
- MK-9470
- NESS-0327
- NIDA-41020
- O-606
- O-1184
- O-1248
- O-1918
- O-2050
- O-2654
- Otenabant (CP-945,598)
- PF-514273
- PipISB
- PSB-SB-487
- Rimonabant (SR141716)
- Rosonabant (E-6776)
- SR-144,528
- Surinabant (SR147778)
- Taranabant (MK-0364)
- TM-38837
- VCHSR
- See also: Cannabinoid receptor modulators (cannabinoids by pharmacology)
- List of: AM cannabinoids
- JWH cannabinoids
- Designer drugs § Synthetic cannabimimetics
